Publikationen in Zusammenarbeit mit Forschern von Universidad Católica de Valencia San Vicente Mártir (16)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

    ESMO Open, Vol. 9, Núm. 3

  3. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

  4. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

  5. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer

    Frontiers in Oncology, Vol. 13

  2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  3. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

    The oncologist, Vol. 28, Núm. 1, pp. 23-32

  4. Top advances of the year: Breast cancer

    Cancer

2021

  1. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  2. Nobody dares stopping clinical research, not even COVID-19

    npj Breast Cancer

  3. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  4. The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”

    Frontiers in Molecular Biosciences, Vol. 8

2020

  1. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019

    European Journal of Cancer, Vol. 135, pp. 62-65

  2. The value of case reports in systematic reviews from rare diseases. The example of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS-II)

    International Journal of Environmental Research and Public Health, Vol. 17, Núm. 18, pp. 1-16

  3. Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): A single-arm, multicenter, phase Ib trial

    Cancers, Vol. 12, Núm. 12, pp. 1-14